Genmab and BioNTech report data from Phase II GCT1046-04 trial for mNSCLC [Yahoo! Finance]
Genmab A/S - American Depositary Shares (GMAB)
Company Research
Source: Yahoo! Finance
Acasunlimab is an investigational bispecific antibody, which aims to elicit an antitumor response through conditional activation of 4-1BB on T cells and natural killer (NK) cells, which is stringently based on simultaneous binding of the PD-L1 arm. The GCT1046-04 clinical trial is an open-label study evaluating the safety and efficacy of acasunlimab in patients with relapsed/refractory mNSCLC. The randomised trial assessed the acasunlimab both as a monotherapy and in combination with pembrolizumab, in patients with PD-L1-positive metastatic non-small cell lung cancer (mNSCLC) who had progressed after one or more previous anti-PD(L)1 containing treatments. The trial showed an overall survival rate of 69% over 12 months, a median overall survival of 17.5 months, and an overall response rate of 30% in patients treated with the combination therapy every six weeks. It involved 113 patients across three arms, with the objective response analysis conducted for 62 centrally confirmed
Show less
Read more
Impact Snapshot
Event Time:
GMAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GMAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GMAB alerts
High impacting Genmab A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GMAB
News
- Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.MarketBeat
- Day One targets the growing ADC market with MabCare acquisition [Yahoo! Finance]Yahoo! Finance
- EHA2024: Odronextamab shows promise in ELM-2 study for follicular lymphoma [Yahoo! Finance]Yahoo! Finance
- EHA 2024: Roche's Columvi competes in BiTE battle with positive results in DLBCL [Yahoo! Finance]Yahoo! Finance
- Ovarian Cancer Pipeline Drugs Analysis, 2024: Insights on 180+ Companies and 200+ Pipeline Drugs, Including Atezolizumab (Genentech), Tisotuma Vedotin (Genmab), and SON-1010 (Sonnet Biotherapeutics) [Yahoo! Finance]Yahoo! Finance